Iron infusions in the community
|
|
- Egbert Daniels
- 6 years ago
- Views:
Transcription
1 i NOTIFICATION Iron infusions in the community 11 September 2017 What we re doing Eligible people will now be able to receive ferric carboxymaltose iron infusions in some general practitioners clinics or other community based settings. We re pleased to inform you about our decision to list ferric carboxymaltose (Ferinject) 50 mg per ml, 10 ml vial in Section B (Community) of the Pharmaceutical Schedule. Patients will need to meet the Special Authority criteria to be eligible to receive the funded medicine. Any changes to the original proposal? This was the subject of a consultation letter dated 2 June 2017, and having carefully considered consultation feedback, we have made the following changes: the decision will take effect from 1 October 2017; and amendments to the proposed access criteria to: o remove the requirement to trial oral iron for some clinical circumstances; and o remove the ferritin limit for applications made by specialists (or on the recommendation of a specialist). Who we think will be most interested This decision will be of interest to community and hospital clinicians, internal medicine physicians, anaesthetists, surgeons, and general practitioners. hospital and community pharmacists, DHBs, suppliers and wholesalers. patients who currently travel to hospital to have an iron infusion in an outpatient setting. A PHARMAC NOTIFICATION 1
2 What will the effect of this decision be? This decision is expected to improve patient health outcomes by providing funded access to ferric carboxymaltose (Ferinject) in primary care. DHBs may gain value from reduced hospital pharmaceutical expenditure, reduced use of blood products related to surgery and reduced demand on hospital outpatient infusion clinics. For patients From 1 October 2017 patients that meet the Special Authority criteria will be eligible for funded ferric carboxymaltose. Ferric carboxymaltose will be dispensed by a community pharmacy on presentation of a prescription. In some cases patients might need to collect it from the pharmacy prior to the administration date and take it with them to the appointment, in others the health service will arrange this. Service availability and costs may also differ between regions, so patients should discuss these matters with their doctor. For community pharmacies From 1 October 2017, pharmacies will be able to dispense ferric carboxymaltose, fully funded, to patients with a valid Special Authority approval. Pharmacies may wish to ask their local general practices if they are providing iron infusions. For hospital pharmacies From 1 October 2017, ferric carboxymaltose will be funded, when dispensed to patients with a valid Special Authority approval. Reimbursement claims can be made (electronically or manually) by pharmacies with a community pharmacy contract claimant number. The Ferinject brand was listed in Section H of the Pharmaceutical Schedule, for inpatient and outpatient use, from 1 August There are no changes to the Section H restrictions. For prescribers From 1 October 2017, ferric carboxymaltose will be funded, subject to Special Authority criteria. A Special Authority can be applied for electronically or manually and the approval number should be printed on the prescription. Prescribers and practices will need to liaise with their DHB regarding delivery of community based infusion services in the DHB region and any accreditation that might be required for a practice to provide DHB funded infusion services. Patients should be advised if there are likely any service charges applicable. PHARMAC notes that the Special Authority criteria are not a clinical guideline for the use of ferric carboxymaltose and the management of iron deficiency anaemia. Prescribers are encouraged to reference their local DHB health pathways (or equivalent guideline) for the management of iron deficiency anaemia. PHARMAC intends to provide support materials for general practice on the management of chronic anaemia and the use of ferric carboxymaltose. For DHBs From 1 October 2017, DHBs will fund the pharmaceutical cost of ferric carboxymaltose for community patients via the Combined Pharmaceutical Budget (managed by A PHARMAC NOTIFICATION 2
3 PHARMAC). PHARMAC has provided supplementary information to DHBs to support this change. Detail of this decision Ferric carboxymaltose (Ferinject) will be listed in Section B of the Pharmaceutical Schedule at the following price and subsidy (ex-manufacturer, excluding GST): Chemical Presentation Brand Pack size Ferric carboxymaltose Inj 50 mg per ml, 10 ml vial Price and subsidy Ferinject 1 $ A confidential rebate will apply to Ferinject, reducing its net price to the Funder (DHBs). Ferric carboxymaltose (Ferinject) will be listed in Section B, subject to the following Special Authority eligibility criteria: Initial application (serum ferritin less than or equal to 20 mcg/l) from any medical practitioner. Approval valid for 3 months for applications meeting the following criteria: 1. Patient has been diagnosed with iron-deficiency anaemia with a serum ferritin level of less than or equal to 20 mcg/l; and 2. Any of the following: 2.1.Patient has been compliant with oral iron treatment and treatment has proven ineffective; or 2.2.Treatment with oral iron has resulted in dose-limiting intolerance; or 2.3.Rapid correction of anaemia is required. Renewal (serum ferritin less than or equal to 20 mcg/l) from any medical practitioner. Approval valid for 3 months for applications meeting the following criteria: 1. Patient continues to have iron-deficiency anaemia with a serum ferritin level of less than or equal to 20 mcg/l; and 2. A re-trial with oral iron is clinically inappropriate. Initial application (iron deficiency anaemia) only from an internal medicine physician, obstetrician, gynaecologist, anaesthetist or a medical practitioner on the recommendation of an internal medicine physician, obstetrician, gynaecologist or anaesthetist. Approval valid for 3 months for applications meeting the following criteria: 1. Patient has been diagnosed with iron-deficiency anaemia; and 2. Any of the following: 2.1. Patient has been compliant with oral iron treatment and treatment has proven ineffective; or 2.2.Treatment with oral iron has resulted in dose-limiting intolerance; or 2.3.Patient has symptomatic heart failure, chronic kidney disease stage 3 or more or active inflammatory bowel disease and a trial of oral iron is unlikely to be effective; or 2.4.Rapid correction of anaemia is required. Renewal (iron deficiency anaemia) only from an internal medicine physician, obstetrician, gynaecologist, anaesthetist or a medical practitioner on the recommendation of an internal medicine physician, obstetrician, gynaecologist or anaesthetist. Approval valid for 3 months for applications meeting the following criteria: 1. Patient continues to have iron-deficiency anaemia; and 2. A re-trial with oral iron is clinically inappropriate. A PHARMAC NOTIFICATION 3
4 For the avoidance of doubt, iron polymaltose will remain listed in both Section B and Section H of the Pharmaceutical Schedule, and iron sucrose will remain listed in Section H. Therefore, clinicians can continue to choose which iron preparation to prescribe, depending on the clinical situation. Our response to what you told us We re really grateful for the time people took to respond to this consultation. All consultation responses received by 21 June 2017 were considered in their entirety when making a decision. The table below summarises the main themes raised in feedback, any changes we have made after listening to you, and other comments on the feedback. If you have any questions, you can us at enquiry@pharmac.govt.nz or call our toll free number (9 am to 5 pm, Monday to Friday) on Theme The Special Authority criteria is very permissive. PHARMAC Comment We are aware that the criteria cover a large patient group and this has been taken into account in our budget impact assessment and forecasting. Evidence was provided to support that a trial of oral iron should not be required first in patients who do not absorb oral iron effectively namely patients with: chronic kidney disease active IBD symptomatic heart failure Patients in general practice that have upcoming surgery should be able to be initiated by a GP and GPs should be entitled to apply for patients with a ferritin >20mcg/L. Haemoglobin thresholds should be included. The requirement for anaemia should be removed for heart failure patients (those with a ferritin under 300 mcg/l are treated) The cause of iron deficiency should be stated on the special authority form. The proposed Special Authority criteria have been amended following consideration of this feedback. Pre-surgical patients will be eligible under criterion 2.3 for rapid correction of anaemia which does not include a timeframe as this should be determined by the treating clinician. Pre-surgical patients with a ferritin greater than 20 mcg/l would be under the care of a specialist and the treating specialist could provide the GP a treatment plan (a recommendation) as to when an iron infusion would be appropriate. PHARMAC sought clinical advice on Special Authority criteria and both PTAC and the Haematology Subcommittee considered haemoglobin levels for inclusion, however the recommendation provided was for criteria that was not inhibitive to different patient groups. PHARMAC considers that removing the requirement for diagnosis with iron-deficiency anaemia would be a much larger group of patients than we have assessed. We intend to seek advice on this feedback from the relevant PTAC Subcommittee. PHARMAC notes that the Special Authority is not intended as a clinical guideline. PHARMAC agrees that the cause for iron deficiency anaemia should be investigated by the treating clinician as part of best practice and recorded in the patient s notes; but we do not consider it should be a criterion for accessing funding. A PHARMAC NOTIFICATION 4
5 Theme Consumables were not included in the proposal and these are also not available on a PSO. There is no clear mechanism for getting the medicine to general practice (uncollected, collected but failed to go to GP, unclear medicolegal accountability for follow ups when non-collection or no-show). Not all GP practices will have the capability and capacity to deliver an infusion service. Some patients may have to find a provider other than their usual GP. Some DHBs are underway with their planning for community infusion services, others are not and considered that the proposed 1 August 2017 list date was not enough time to plan for such a transition. Some DHBs noted that they have not allocated budget for this service to be provided in the community and noted that reducing hospital based infusions may appear as a saving but this does not produce monetary saving for the hospital. If a patient charge was applicable to either the medicine ($5 pharmacy co-payment) or the service/administration (which could be more than $100) this could lead to inequities based on a patient s ability to pay. One DHB considered there was a National policy, with respect to services shifting from secondary to primary care, that they must remain free to the patient. PHARMAC Comment PHARMAC considers that the cost of consumables would be part of the infusion service costs. PHARMAC note that utilising pharmacy for the distribution of ferric carboxymaltose was the only current option available to progress funding in the community setting via a claiming and reimbursement model. PHARMAC acknowledges that it is unlikely that all general practices will provide infusion services, we note that an increasing number of general practices are providing infusions for patients. DHBs that have systems in place now will have no barrier to accessing funded pharmaceutical in the community. Those that are not able to offer funded community based infusions are not required to be ready on 1 October These DHBs can continue to provide patients with ferric carboxymaltose in a hospital outpatient setting, or as alternatively arranged, as they are currently doing. DHB Hospitals will be able to claim reimbursement for the cost of the pharmaceutical for hospital outpatients who have Special Authority approvals via the Combined Pharmaceutical Budget, reducing DHB Hospitals pharmaceutical expenditure. Additionally, where services shift from hospital to the community setting, hospital pharmaceutical expenditure would also reduce although the cost to the funder would remain. PHARMAC acknowledges that freeing up infusion capacity is not realised as monetary savings for DHB Hospitals. Noted. This issue was also raised during the 2014 consultation on the hospital listing and PHARMAC committed to engaging with stakeholders to discuss this further. Since 2014 PHARMAC has explored whether a community based funding and reimbursement model for pharmaceuticals delivered in primary care could be developed. As yet this has not been resolved. PHARMAC is now in a budget position to progress a community listing and intends to continue engaging with relevant health sector stakeholders about development of a community based claiming and reimbursement model for pharmaceuticals. There are no changes to the Section H restrictions for hospitals. Therefore, eligible patients could continue to access funded ferric carboxymaltose treatment via DHB hospitals in outpatient clinics if community infusions services are cost prohibitive. Noting that inexpensive oral and intramuscular forms of iron will still be available for clinicians to provide. This decision would not change any current expectations or Crown funding agreements in place regarding DHB service provision charges. PHARMAC anticipates that DHBs would have regard to any such expectations when developing options for local service provision. A PHARMAC NOTIFICATION 5
6 Theme This proposal does not address what training in or accreditation is required. PHARMAC Comment PHARMAC will be engaging with primary care to develop educational materials to support the introduction of ferric carboxymaltose via agreements with Goodfellow and BPAC. A PHARMAC NOTIFICATION 6
Why Iron? Iron is the Most prevalent micronutrient deficiency in the world (WHO 1968)
Why Iron? Iron is the Most prevalent micronutrient deficiency in the world (WHO 1968) Iron deficiency anaemia is a Major reason for blood being transfused Iron deficiency without anaemia is 3 times as
More informationRequest for information on a proposal to fund compression bandages and hosiery for the treatment of venous leg ulcers
24 May 2013 Request for information on a proposal to fund compression bandages and hosiery for the treatment of venous leg ulcers PHARMAC is interested in receiving information from suppliers, DHBs, service
More informationREQUEST FOR PROPOSALS SUPPLY OF FENTANYL TRANSDERMAL PATCHES. PHARMAC invites proposals for the supply of fentanyl transdermal patches in New Zealand.
2 August 2007 Dear Supplier REQUEST FOR PROPOSALS SUPPLY OF FENTANYL TRANSDERMAL PATCHES PHARMAC invites proposals for the supply of fentanyl transdermal patches in New Zealand. This request for proposals
More informationPost-operative and Discharge Pathways for PBM Claire L J Atterbury CNS Transfusion and Haematology
Post-operative and Discharge Pathways for PBM Claire L J Atterbury CNS Transfusion and Haematology 1 Plan for the worst and hope for the best claire.atterbury@qehkl.nhs.uk 2 Where were we? What year? The
More informationNHS PCA (P) (2015) 17. Dear Colleague
Healthcare Quality and Strategy Directorate Pharmacy and Medicines Division Dear Colleague PHARMACEUTICAL SERVICES AMENDMENTS TO DRUG TARIFF IN RESPECT OF SPECIAL PREPARATIONS AND IMPORTED UNLICENSED MEDICINES
More informationNHS PCA (P) (2015) 17 ANNEX B. Specials Frequently Asked Questions for Community Pharmacy. Pre-authorisation:
ANNEX B Specials Frequently Asked Questions for Community Pharmacy Pre-authorisation: Q: When do I need to seek authorisation? A: You need to seek authorisation for all Specials manufactured medicines
More informationSouth East London Interface Prescribing Policy including the NHS and Private Interface Prescribing Guide
South East London Interface Prescribing Policy including the NHS and Private Interface Prescribing Guide 1. Introduction 1.1 This policy has been developed by the South East London Clinical Commissioning
More informationImproving compliance with oral methotrexate guidelines. Action for the NHS
Patient safety alert 13 Alert Immediate action Action Update Information request Ref: NPSA/2006/13 Improving compliance with oral methotrexate guidelines Oral methotrexate is a safe and effective medication
More informationLocal Implementation Plan for Supply of Stoma Appliances in the Community from April Draft. Version 1 October
Local Implementation Plan for Supply of Stoma Appliances in the Community from April 2006 Draft Version 1 October 2005 1 Contents Background National Procurement and Funding Status of Sponsored or Company
More informationGENERAL INFORMATION INDEX
INDEX INDEX...3 GENERAL... 4 1. SCOPE & APPLICATION OF THE SCOTTISH DRUG TARIFF... 4 2. FREQUENCY OF PUBLICATION... 5 3. DETAILS OF AMENDMENTS SINCE LAST PUBLISHED EDITION... 5 4. REQUIREMENT ON NHS BOARDS
More informationPopulation. 4.1 million People Maori 14% Pacific People 6% Asian 6% 39.9 million sheep
Population 4.1 million People Maori 14% Pacific People 6% Asian 6% 39.9 million sheep Paul Cressey The New Zealand Health System New Zealand Health Information emedicine NZ Context Safe Medication Management
More informationRecommendations from National Patient Safety Agency alerts that remain relevant to the Never Events list 2018
Recommendations from National Patient Safety Agency alerts that remain relevant to the Never Events list 2018 January 2018 We support providers to give patients safe, high quality, compassionate care within
More informationChapter 3 Products, Networks, and Payment Unit 4: Pharmacy and Formulary
Chapter 3 Products, Networks, and Payment Unit 4: Pharmacy and Formulary In This Unit Topic See Page Unit 4: Pharmacy and Formulary Pharmaceutical Overview 2 Pharmaceutical 3 Drug 4 NOTE: This section
More informationChapter 2 Provider Responsibilities Unit 6: Behavioral Health Care Specialists
Chapter 2 Provider Responsibilities Unit 6: Health Care Specialists In This Unit Unit 6: Health Care Specialists General Information 2 Highmark s Health Programs 4 Accessibility Standards For Health Providers
More informationRULES OF TENNESSEE DEPARTMENT OF LABOR AND WORKFORCE DEVELOPMENT WORKERS COMPENSATION DIVISION
RULES OF TENNESSEE DEPARTMENT OF LABOR AND WORKFORCE DEVELOPMENT WORKERS COMPENSATION DIVISION CHAPTER 0800-02-25 WORKERS COMPENSATION MEDICAL TREATMENT TABLE OF CONTENTS 0800-02-25-.01 Purpose and Scope
More informationNPSA Alert 03: Reducing the harm caused by oral Methotrexate. Implementation Progress Report July Learning and Sharing
NPSA Alert 03: Reducing the harm caused by oral Methotrexate Implementation Progress Report July 2006 Learning and Sharing CONTENTS Page 1 Background 3 2 Findings 4 Appendix 1 Summary of responses 6 Appendix
More informationPrescribing Controlled Drugs: Standard Operating Procedure
Clinical Prescribing Controlled Drugs: Standard Operating Procedure Document Control Summary Status: Version: Author/Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic Aims Implementation
More information78th OREGON LEGISLATIVE ASSEMBLY Regular Session. House Bill 2028 SUMMARY
Sponsored by COMMITTEE ON HEALTH CARE th OREGON LEGISLATIVE ASSEMBLY-- Regular Session House Bill SUMMARY The following summary is not prepared by the sponsors of the measure and is not a part of the body
More informationPhysician Payments Disclosure and Aggregate Spend:
Physician Payments Disclosure and Aggregate Spend: Navigating Conflicting and Unclear State Laws and Regulations A Guide for Device Manufacturers October 26, 2010 Colin J. Zick Foley Hoag LLP czick@foleyhoag.com
More informationClinical pharmacists in general practice links with community pharmacy
Introduction Pharmacists employed in the GP clinical pharmacist NHS England programme are encouraged to complete online activity recording. One of the activities records how they are working with community.
More informationPHARMAC has withheld some material from this Minute in accordance with section 6a of the Official Information Act 1982
PHARMAC has withheld some material from this Minute in accordance with section 6a of the Official Information Act 1982 Minutes of the PHARMAC Consumer Advisory Committee (CAC) meeting Friday 6 March 2009
More informationSafer use of anticoagulants: the NPSA patient safety alert Steve Chaplin MSc, MRPharmS
Safer use of anticoagulants: the NPSA patient safety alert Steve Chaplin MSc, MRPharmS Steve Chaplin describes the NPSA s anticoagulant patient safety alert and the measures it recommends for making the
More informationNational clinical audit of inpatient care for adults with ulcerative colitis
National clinical audit of inpatient care for adults with ulcerative colitis UK inflammatory bowel disease (IBD) audit Executive summary report June 2014 Prepared by the Clinical Effectiveness and Evaluation
More informationSCHEDULE 2 THE SERVICES
SCHEDULE 2 THE SERVICES A. Service Specifications Service Specification No. 170008/S Service Atypical haemolytic uraemic syndrome (ahus) (all ages) Commissioner Lead Provider Lead Period Date of Review
More informationQuality Medication Use in Aboriginal Communities
Quality Medication Use in Aboriginal Communities Lance Emerson, Kathy Bell, Roland Manning 5th National Rural Health Conference Adelaide, South Australia, 14-17th March 1999 Lance Emerson Proceedings Quality
More informationOxfordshire Anticoagulation Service. Important information about anticoagulation with vitamin K antagonists Information for patients
Oxfordshire Anticoagulation Service Important information about anticoagulation with vitamin K antagonists Information for patients Page 2 Your information Name:... Address:......... or patient stickie
More informationPharmacist (Palliative Care) December 2014 Page 1
Job Profile Job Title: Department: Main Location: Hospice Palliative Care Pharmacist 7 NHS (8SRC) Less than full time(0.8) Full time equivalent around 36,300 Head of Clinical Services 1. Main Purpose of
More informationNumber and costs of prescription items
Number of prescritpion items (m) Cost of prescriptions ( m) HSC Efficiencies - Prescribing in primary/secondary care 1 Introduction 1.1 Purpose It has been reported that there is an expected overspend
More informationMinutes of the PHARMAC Consumer Advisory Committee (CAC) meeting Wednesday 24 October 2012
Minutes of the PHARMAC Consumer Advisory Committee (CAC) meeting Wednesday 24 October 2012 The meeting was held at PHARMAC, 9th floor, 40 Mercer St, Wellington from 9.45 am. Present: Kate Russell Anne
More informationCorporate/General Finance
Document title: Policy and Guidance for Joint Working with the Pharmaceutical Industry (including rebate schemes) & Commercial Sponsorship of Meetings/Training Events CCG document ref: Author / originator:
More informationSPONSORSHIP AND JOINT WORKING WITH THE PHARMACEUTICAL INDUSTRY
SPONSORSHIP AND JOINT WORKING WITH THE PHARMACEUTICAL INDUSTRY 1 SUMMARY This document sets out Haringey Clinical Commissioning Group policy and advice to employees on sponsorship and joint working with
More informationUnlicensed Medicines Policy Document
Unlicensed Medicines Policy Document Effective: February 2002 (Intranet 2006) Review date: February 2007 A. Introduction In order to ensure that medicines are safe and effective the manufacture and sale
More informationOutcomes from the Business Case Sub Committee 8 th February 2013
Outcomes from the Business Case Sub Committee 8 th February 2013 Business Case Summary Committee Decision Designated Nurse Child Transfer of post from Your Healthcare (YHC) to Safeguarding Kingston CCG.
More informationGuidelines for patients undergoing surgery as part of an Enhanced Recovery Programme (ERP)
Guidelines for patients undergoing surgery as part of an Enhanced Recovery Programme (ERP) Summary Helping you to get better sooner after surgery June 2012 Foreword These guidelines have been produced
More informationMEDICINES RECONCILIATION GUIDELINE Document Reference
MEDICINES RECONCILIATION GUIDELINE Document Reference G358 Version Number 1.01 Author/Lead Job Title Jackie Stark Principle Pharmacist Clinical Services Date last reviewed, (this version) 29 November 2012
More informationBest Practice Guidance for Supplementary Prescribing by Nurses Within the HPSS in Northern Ireland. patient CMP
Best Practice Guidance for Supplementary Prescribing by Nurses Within the HPSS in Northern Ireland patient CMP nurse doctor For further information relating to Nurse Prescribing please contact the Nurse
More informationLegal limitations for nurse prescribers: a focus on dispensing. Andy Gray Division of Pharmacology Discipline of Pharmaceutical Sciences
Legal limitations for nurse prescribers: a focus on dispensing Andy Gray Division of Pharmacology Discipline of Pharmaceutical Sciences Outline What is prescribing? What is dispensing? Enabling legal frameworks
More informationThe University of North Carolina Wilmington PHYSICIAN ASSISTANT COMPETENCY PROFILE
The University of North Carolina Wilmington PHYSICIAN ASSISTANT COMPETENCY PROFILE Description of Work: Positions in this class provide patient evaluation and care in area of assignment. Duties include
More informationPrescribing Policy between Nottinghamshire Commissioning Organisations and local providers of NHS Services
Prescribing Policy between Nottinghamshire Commissioning Organisations and local providers of NHS Services Document Purpose Version 2.2 To detail the specific contractual issues associated with prescribing
More informationDefinitions: In this chapter, unless the context or subject matter otherwise requires:
CHAPTER 61-02-01 Final Copy PHARMACY PERMITS Section 61-02-01-01 Permit Required 61-02-01-02 Application for Permit 61-02-01-03 Pharmaceutical Compounding Standards 61-02-01-04 Permit Not Transferable
More informationNON-MEDICAL PRESCRIBING POLICY
NON-MEDICAL PRESCRIBING POLICY To be read in conjunction with the Medicines Policy, Controlled Drug Policy and the FP10 Prescribing Forms Policy Version: 5 Date of issue: August 2017 Review date: August
More informationUsing Practitioner Supply Orders and Standing Orders in the Rheumatic Fever Prevention Programme. Guidance for sore throat management services
Using Practitioner Supply Orders and Standing Orders in the Rheumatic Fever Prevention Programme Guidance for sore throat management services February 2015 Citation: Ministry of Health. 2015. Using Practitioner
More informationLSU First & WebTPA: Working Together
LSU First & WebTPA: Working Together 2016 LSU First Health Plan Changes 2016 LSU First Health Plan Changes New ID Card Specialty drug copay $150 90 day timely filing period (medical and pharmacy) Home
More informationAlert. Patient safety alert. Actions that can make anticoagulant therapy safer. 28 March Action for the NHS and the independent sector
Patient safety alert 18 Alert 28 March 2007 Immediate action Action Update Information request Ref: NPSA/2007/18 Actions that can make anticoagulant therapy safer Anticoagulants are one of the classes
More informationFUNDING FOR TREATMENT IN THE EEA APPLICATION FORM
FUNDING FOR TREATMENT IN THE EEA APPLICATION FORM Please note: NHS England can only process claims for residents ordinarily resident in England. Reimbursements will only be granted for eligible treatment
More informationThe Swedish national courts administration. data/assets/pdf_file/0020/96410/e73430.pdf
Sweden European Region Updated: February 2017 This document contains links to websites where you can find national legislation and health laws. We link to official government legal sources wherever possible.
More informationAuthorisation to Administer Medicines
Authorisation to Administer Medicines Health Guidance Publication date: March 2016 This information sheet is produced for the guidance of Care Inspectorate staff only. The contents should not be regarded
More informationBioMarin Patient and Physician Support (BPPS) Enrollment Forms for KUVAN
BioMarin Patient and Physician Support (BPPS) Enrollment Forms for KUVAN Instructions for Completing Statement of Medical Necessity (SMN) and Prescription for KUVAN If you need assistance with the attached
More informationNewfoundland and Labrador Pharmacy Board
Newfoundland and Labrador Pharmacy Board Standards of Practice Prescribing by Pharmacists August 2015 Table of Contents 1) Introduction... 1 2) Requirements... 1 3) Limitations... 1 4) Operational Standards...
More informationAn Overview for F2 Doctors of Foundation Programme attachments to General Practice
An Overview for F2 Doctors of Foundation Programme attachments to General Practice July 2011 Contents Page GP Placements 2 Guidance on Educational Agreements 4 Key facts about F2 Placements 6 The Foundation
More informationRegister No: Status: Public on ratification
Private Patient Policy Type: Policy Register No: 12024 Status: Public on ratification Developed in response to: Service Development Contributes to CQC Outcome number: 4 Consulted With Post/Committee/Group
More informationExpanding Your Pharmacist Team
CALIFORNIA QUALITY COLLABORATIVE CHANGE PACKAGE Expanding Your Pharmacist Team Improving Medication Adherence and Beyond August 2017 TABLE OF CONTENTS Introduction and Purpose 1 The CQC Approach to Addressing
More informationPharmacy Services within the Hospital
Pharmacy Services within the Hospital Pharmacy Department Clinical Support Services This leaflet has been designed to give you important information and to answer some common queries that you may have.
More informationGood Practice Principles:
NHMC National Homecare Medicines Committee Good Practice Principles: Provision of Manufacturer Funded Homecare Medicines Services National Homecare Medicines Committee February 2018 Version 1 Definitions
More informationResponsible pharmacist requirements: What activities can be undertaken?
requirements: What activities can be undertaken? Status of this document This guidance is intended to assist the profession in implementing the responsible requirements within registered premises. 1 Appendix
More informationUncontrolled when printed NHS AYRSHIRE & ARRAN CODE OF PRACTICE FOR MEDICINES GOVERNANCE. SECTION 9(a) UNLICENSED MEDICINES
Uncontrolled when printed NHS AYRSHIRE & ARRAN CODE OF PRACTICE FOR MEDICINES GOVERNANCE SECTION 9(a) UNLICENSED MEDICINES BACKGROUND and PURPOSE Under the Medicines Act 1968 (EEC Directive 65/65), a company
More informationOverview of Select Health Provisions FY 2015 Administration Budget Proposal
Overview of Select Health Provisions FY 2015 Administration Budget Proposal On March 4, 2014, President Obama released his Administration s FY 2015 budget proposal to Congress. The budget contains a number
More informationImplementing QIPP in care homes Hounslow PCT approach - Delivering positive clinical and cost effective outcomes
Implementing QIPP in care homes Hounslow PCT approach - Delivering positive clinical and cost effective outcomes Unoma Okoli Care Home Pharmacist, Hillingdon PCT unoma.okoli@nhs.net Background CHUMS-Care
More informationScotia College of Pharmacists Standards of Practice. Practice Directive Prescribing of Drugs by Pharmacists
Scotia College of Pharmacists Standards of Practice Practice Directive Prescribing of Drugs by Pharmacists September 2014 ACKNOWLEDGEMENTS This Practice Directives document has been developed by the Prince
More informationE-Prescribing, Formulary Searching and Exception Requests for MDwise Plans
E-Prescribing, Formulary Searching and Exception Requests for MDwise Plans E-Prescribing Together with its pharmacy benefits managers (PBMs), MedImpact and PerformRx, MDwise provides physicians and other
More informationSpecialty Pharmacy How is Traditional Pharmacy Practice Positioned
Specialty Pharmacy How is Traditional Pharmacy Practice Positioned Nick Calla Vice President, Industry Relations Cardinal Health Specialty Solutions August 19, 2016 Today s Learning Objectives Understand
More informationNational Programme for IT. Ken Lunn Head of Comms and Messaging OMG/HL7 workshop October 2005
National Programme for IT Ken Lunn Head of Comms and Messaging OMG/HL7 workshop 25-27 October 2005 Contents Context Our aims What is the National Programme for IT? Implementation Benefits Questions In
More informationOklahoma Health Care Authority (OHCA) Pharmacy Provider Attestation Hemophilia and Other Rare Bleeding Disorders Standards of Care
Page 1 Oklahoma Health Care Authority (OHCA) Pharmacy Provider Attestation Hemophilia and Other Rare Bleeding Disorders Standards of Care In order to be reimbursed for providing factor replacement products
More informationMedicine and Supporting Pupils at School with Medical Conditions Policy
Medicine and Supporting Pupils at School with Medical Conditions Policy This Policy is founded within our School ethos which provides a caring, friendly and safe environment for all members of our community.
More informationAppendix 2. Community Pharmacy Emergency Hormonal Contraception Service
Appendix 2 Community Pharmacy Emergency Hormonal Contraception Service 2014 until end November 2016 Contents Executive Summary... 3 Aims and intended service outcomes of the service... 3 Brief service
More informationInflammatory bowel disease service. Information for patients
Inflammatory bowel disease service Information for patients We ve written this leaflet to explain about our inflammatory bowel disease (IBD) service. If you have ulcerative colitis, Crohn s disease or
More informationNHS Summary Care Record. Guide for GP Practice Staff
NHS Summary Care Record Guide for GP Practice Staff NHS Summary Care Record Guide for GP Practice Staff v1.2 October 2012 Table of Contents 1 Introduction to this guide...3 2 Overview of the Summary Care
More informationSave up to $4,000 a year?!
Save up to $4,000 a year?! Indication and Usage HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] is an immune globulin with a recombinant human hyaluronidase indicated
More informationJOB DESCRIPTION. Progressive: A learning organization, encouraging innovation and continuous improvement.
JOB DESCRIPTION Job Title: Medicines Management Support Assistant Pay Band: Band 3 Hours of Work: Responsible to: Accountable to: Base Point: Contract Type 37.5 hours per week Prescription Order Line Manager
More informationPrimary & Secondary Care Interface Issues. Safety In Practice Learning Session 4 27th June 2016
Primary & Secondary Care Interface Issues Safety In Practice Learning Session 4 27th June 2016 GPs feel that some referrals are not dealt with appropriately Barriers to admitting a patient acutely Long
More informationST PAUL S CATHOLIC PRIMARY SCHOOL AND NURSERY. Supporting Pupils with Medical Conditions Policy
ST PAUL S CATHOLIC PRIMARY SCHOOL AND NURSERY Supporting Pupils with Medical Conditions Policy Our Mission Statement Do everything with love. (St Paul s first letter to the Corinthians 16:14) This means
More informationReview of Local Enhanced Services
Review of Local Enhanced Services 1. Background and context 1.1 CCGs are required to prepare for the phasing out of LESs by April 2014 by reviewing the existing LES portfolio and developing commissioning
More informationNHS Fife. Patient Group Direction for Named Community Pharmacists to Supply
Patient Group Direction for Named Community Pharmacists to Supply Senna tablets 7.5mg or Senna syrup 7.5mg/5ml (Total sennosides calculated as sennoside B) For patients aged 16 years and older prescribed
More informationAudit Data Collection Form
pecialist Pharmacy ervice Medicines Use and afety Audit Data Collection Form Collaborative audit across England on the quality of medication related information provided when transferring patients from
More informationAppendix 1. Immediate Postpartum Long-Acting Reversible Contraception (LARC)
Appendix 1. Immediate Postpartum Long-Acting Reversible Contraception (LARC) Program Implementation Guide: Exploration Stage Implementation Guide Overview Each stage of the implementation guide is organized
More informationNATIONAL PROFILES FOR PHARMACY CONTENTS
NATIONAL PROFILES FOR PHARMACY CONTENTS Profile Title AfC Banding Page Pharmacy Support Worker Pharmacy Support Worker Higher Level Pharmacy Technician 4 4 Pharmacy Technician Higher level 5 5 Pharmacist
More informationQOF Quality and Productivity (QP) Indicators. Supplementary Guidance and Frequently Asked Questions for PCTs and Practices in England
QOF Quality and Productivity (QP) Indicators Supplementary Guidance and Frequently Asked Questions for PCTs and Practices in England May 2011 Contents Introduction 2 Summary of QP indicators 3 Prescribing
More informationEvaluation of Pharmacy Delivery Models
Evaluation of Pharmacy Delivery Models As Required By House Bill 1, 84th Legislature, Regular Session, 2015 (Article II, Health and Human Services Commission, Rider 83) Health and Human Services Commission
More informationLewisham Integrated Medicines Optimisation Service
Lewisham Integrated Medicines Optimisation Service By Kath Howes (CCG) & Kay Fahy (University Hospital Lewisham) Katherine.howes@nhs.net LIMOS: 02030493228 Seen this before??- Hoarding & Wastage The Story
More informationPROTOCOL FOR THE ADMINISTRATION OF SENNA. Formulary and Prescribing Guidelines
PROTOCOL FOR THE ADMINISTRATION OF SENNA Formulary and Prescribing Guidelines Introduction This protocol allows for the administration of Senna by a registered nurse without a prescription from a doctor
More informationEnsuring our safeguarding arrangements act to help and protect adults PRACTICE GUIDANCE FOR REPORTING MEDICATION INCIDENTS INTO SAFEGUARDING
Ensuring our safeguarding arrangements act to help and protect adults PRACTICE GUIDANCE FOR REPORTING MEDICATION INCIDENTS INTO SAFEGUARDING Contents Page 1.0 Purpose 2 2.0 Definition of medication error
More informationACG GI Practice Toolbox
ACG GI Practice Toolbox Setting Up an Ambulatory Infusion Center in Your Practice AUTHOR: David L. Limauro, MD, University of Pittsburgh Medical Center, Pittsburgh, PA INTRODUCTION: Private practices in
More informationNational Cancer Action Team. National Cancer Peer Review Programme EVIDENCE GUIDE FOR: Colorectal MDT. Version 1
National Cancer Action Team National Cancer Peer Review Programme FOR: Version 1 Introduction This evidence guide has been formulated to assist Networks and their constituent teams in preparing for peer
More informationCCG Policy for Working with the Pharmaceutical Industry
CCG Policy for Working with the Pharmaceutical Industry 1. Introduction Medicines are the most frequently and widely used NHS treatment and account for over 12% of NHS expenditure. The Pharmaceutical Industry
More informationLong Term Care Group Services Organizations Not Just for Nursing Home Providers Anymore
Long Term Care Group Services Organizations Not Just for Nursing Home Providers Anymore Presented by: Denny Sherrill, Vice President, GeriMed John Schutte, President, GeriMed 2:15 p.m. - 3:45 p.m., Tuesday,
More informationSupporting Children at School with Medical Conditions
Introduction Children and young people with medical conditions are entitled to a full education and have the same rights of admission to school as other children. This means that no child with a medical
More informationSystemic anti-cancer therapy Care Pathway
Network Guidance Document Status: Expiry Date: Version Number: Publication Date: Final July 2013 V2 July 2011 Page 1 of 9 Contents Contents... 2 STANDARDS FOR PREPARATION AND PHARMACY... 3 1.1 Facilities
More informationNon Medical Prescribing Policy
Non Medical Prescribing Policy Author: Sponsor/Executive: Responsible committee: Ratified by: Consultation & Approval: (Committee/Groups which signed off the policy, including date) This document replaces:
More informationNHS Lanarkshire Policy for the Availability of Unlicensed Medicines
NHS Lanarkshire Policy for the Availability of Unlicensed Medicines Prepared by: NHS Lanarkshire Chief Pharmacist Endorsed by: Area Drug & Therapeutic Committee Previous Version/Date: Primary Policy Date:
More informationAN ACT. Be it enacted by the General Assembly of the State of Ohio:
(131st General Assembly) (Substitute House Bill Number 124) AN ACT To amend section 4729.01 and to enact sections 4723.4810, 4729.282, 4730.432, and 4731.93 of the Revised Code regarding the authority
More informationSubtitle E New Options for States to Provide Long-Term Services and Supports
LONG TERM CARE (SECTION-BY-SECTION ANALYSIS) (Information compiled from the Democratic Policy Committee (DPC) Report on The Patient Protection and Affordable Care Act and the Health Care and Education
More informationCommunity Intravenous Therapy Referral Standards
pecialist harmacy ervice Medicines Use and afety Community Intravenous Therapy Referral tandards Background A multi-centred audit of prescribing and administration of community IV therapy across East and
More informationTribal Best Practices and Critical Issues: Medicaid Pharmacy Reimbursement for IHS / Tribal / Urban Indian Health Programs
Tribal Best Practices and Critical Issues: Medicaid Pharmacy Reimbursement for IHS / Tribal / Urban Indian Health Programs February 28, 2018 Tribal Self Governance Advisory Committee TribalSelfGov.org
More information79th OREGON LEGISLATIVE ASSEMBLY Regular Session. Enrolled
79th OREGON LEGISLATIVE ASSEMBLY--2017 Regular Session Enrolled House Bill 2527 Sponsored by Representative BUEHLER, Senator STEINER HAYWARD; Representatives HACK, KENY-GUYER, SOLLMAN, Senator MONNES ANDERSON
More informationMEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL SCHEDULING OF SUBSTANCES FOR PRESCRIBING BY AUTHORISED PRESCRIBERS This document provides guidance on the process for amending the Schedules to the Medicines and Related Substances
More informationCommercial Risk Adjustment (CRA) Enrollee Health Assessment Program. Provider User Guide. Table of Contents
Commercial Risk Adjustment (CRA) Enrollee Health Assessment Program Provider User Guide Table of Contents 1. Commercial Risk Adjustment (CRA)... 2 2. Enrollee Health Assessment (EHA) Program... 2 3. Program
More informationSummary of Benefits [Silver Access+ HMO 1750/55 OffEx] [Silver Local Access+ HMO 1750/55 OffEx]
Blue Shield of California is an independent member of the Blue Shield Association Summary of Benefits [Silver Access+ HMO 1750/55 OffEx] [Silver Local Access+ HMO 1750/55 OffEx] Group Plan HMO Benefit
More informationDo you suffer from diabetes? Do you want to shape the future of diabetes care?
Do you suffer from diabetes? Do you want to shape the future of diabetes care? MSD has fully funded this project which is a collaboration between MSD, Heart of England Foundation Trust, Lloyds Pharmacy
More informationResearched Medicines Industry Association of New Zealand Incorporated. Submission on Pharmacist Prescribers
Researched Medicines Industry Association of New Zealand Incorporated Submission on Pharmacist Prescribers July 2010 Researched Medicines Industry Association of New Zealand Incorporated Level 8, 86-90
More informationPHARMACIST INDEPENDENT PRESCRIBING MEDICAL PRACTITIONER S HANDBOOK
PHARMACIST INDEPENDENT PRESCRIBING MEDICAL PRACTITIONER S HANDBOOK 0 CONTENTS Course Description Period of Learning in Practice Summary of Competencies Guide to Assessing Competencies Page 2 3 10 14 Course
More information